Evidence map›Paper›PMID 37242998›Full record

ArticleVaccines2023

Humoral Response after a Fourth Dose with mRNA-1273 in Healthcare Workers with and without a History of SARS-CoV-2 Infection and Previously Vaccinated with Two Doses of BBIBP-CorV Plus BNT162b2 Vaccine.

Juan C Gómez de la Torre, Miguel Hueda-Zavaleta, José Alonso Cáceres-DelAguila, Cecilia Muro-Rojo, Nathalia De La Cruz-Escurra, Vicente A Benítes-Zapata

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Juan C Gómez de la TorreRoe Clinical Laboratory, Dos de Mayo Avenue, 1741, San Isidro, Lima 15076, Peru.ORCID 0000-0003-4566-2027
Miguel Hueda-ZavaletaHospital III Daniel Alcides Carrión, Essalud, Calana Road, Km 6.5, Calana, Tacna 23000, Peru.ORCID 0000-0002-8049-7787
José Alonso Cáceres-DelAguilaRoe Clinical Laboratory, Dos de Mayo Avenue, 1741, San Isidro, Lima 15076, Peru.ORCID 0000-0001-7897-5033
Cecilia Muro-RojoRoe Clinical Laboratory, Dos de Mayo Avenue, 1741, San Isidro, Lima 15076, Peru.
Nathalia De La Cruz-EscurraRoe Clinical Laboratory, Dos de Mayo Avenue, 1741, San Isidro, Lima 15076, Peru.
Vicente A Benítes-ZapataUnidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola, La Fontana Avenue 550, La Molina, Lima 15024, Peru.ORCID 0000-0002-9158-1108
Daniel Alcides Carrión National University · PEUniversidad San Ignacio de Loyola · PE

Funding

CSRD VA 1
6 · The paper itself

Abstract

There is limited information on the kinetics of the humoral response elicited by a fourth dose with a heterologous mRNA1273 booster in patients who previously received a third dose with BNT162b2 and two doses of BBIBP-CorV as the primary regimen. We conducted a prospective cohort study to assess the humoral response using Elecsys

Indexed as

COVID-19heterologous booster vaccinehumoral immunityneutralizing antibodySARS-CoV-2vaccine breakthrough infection

Identifiers

PMID37242998
PMCPMC10221616
OpenAlexW4366987885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.